SLC5A2 and Menkes disease: Despite these limitations, our findings provide compelling preliminary evidence supporting the potential repurposing of SGLT-2 inhibitors as a therapeutic candidate in treatment-resistant MD, warranting further investigation through properly designed clinical trials.